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Lymphangiogenesis and the expression of vascular endothelial cell growth factor C (VEGF-C) in tumors have been considered to
be causally promoting lymphatic metastasis. There are only a few studies on lymphatic metastasis in immunocompetent allograft
mouse models. To study the relationship between VEGF-C-mediated lymphangiogenesis and axillary lymph node metastasis, we
used two mouse mammary carcinoma cell lines; the BJMC338 has a low metastatic propensity, whereas the BJMC3879 has a
high metastatic propensity although it originated from the former cell line. Each cell line was injected separately into two groups
of female BALB/c mice creating in vivo mammary cancer models. The expression level of VEGF-C in BJMC3879 was higher than
BJMC338.Astheparentcellline,BJMC3879-derivedtumorsshowedhigherexpressionofVEGF-CcomparedtoBJMC338-derived
tumors. This higher expression of VEGF-C in BJMC3879-derived tumors was associated with marked increase in inﬁltrating
macrophages and enhanced expression of lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) reﬂecting increased
tumoral lymphatic density and subsequent induction of axillary lymph node metastasis. Our mouse mammary carcinoma models
are allotransplanted tumors showing the same axillary lymph node metastatic spectrum as human breast cancers. Therefore, our
mouse models are ideal for exploring the various molecular mechanisms of cancer metastasis.
1.Introduction
Based on clinical and pathological observations in human
mammary carcinomas, the metastatic spread of mammary
carcinoma cells is responsible for the majority of cancer
deaths [1–5]. The common pathway of initial cancer dis-
semination is via lymphatics due to their characteristic
endothelial structure with blind-ending capillaries [6]. In
addition, metastasis to the regional lymph nodes through
the lymphatic vessels is considered to be a common step
in the progression of cancer and an important prognostic
factor in many types of cancer including breast carcinomas.
Lymphaticvesseldensity(LVD)inmanytypesofsolidcancer
is associated with lymph node metastasis or poor prognosis,
as has been reported in experimental and clinical studies
[1–5, 7, 8]. Although mammary carcinoma is well known
to have the character for lymph node metastasis, there are
only a few mouse mammary carcinoma models showing
extensive metastasis to lymph nodes. The chick embryo
chorioallantoic membrane [9] and immunodeﬁcient mice,
SCIDmic e,orn udemic ew er eusedasx enotransplant edhost
animals to examine metastasis [10–12]. Recent studies have
showntheimportant rolesoftumor-associated macrophages
(TAMs) expressing CD68 in cancer-mediated lymphangio-
genesis [13–15]. Accordingly, the mouse immunocompetent
model appears to be necessary for studying lymphangiogen-
esis and lymph node metastasis.
The vascular endothelial growth factor C (VEGF-C) is
a major lymphangiogenic factor. There is some evidence
that VEGF-C promotes lymphangiogenesis under several2 International Journal of Breast Cancer
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Figure 1: TEM micrographs (a and b), immunoﬂuorecent staining (c and d), Western blot analysis (e), and RT-PCR analysis (f) of VEGF-
C in the two-mouse mammary carcinoma cell lines. Both BJMC338 cells (a) and BJMC3879 cells (b) have the similar ultrastructure.
BJMC338 cells (c) have minimally any activity of VEGF-C, whereas BJMC3879 cells (d) have moderate expression. Western blot analysis
(e) demonstrates the same activity of VEGF-C as in (c and d). VEGF-C mRNA expression in BJMC3879 cells is higher than that of BJMC338
cells (f). Green ﬂuorescence (FITC) indicates activity of VEGF-C, and red ﬂuorescence (PI) shows nuclei of cells in (c and d).
normal and pathological conditions [16]. In VEGF-C-
deﬁcient mouse embryos, lymphatic vessels fail to develop
from veins [17] resulting in prenatal death owing to ﬂuid
accumulation in the tissues of mouse embryos and edema
in adults [18]. On the other hand, in VEGF-C transgenic
mice,hyperplasiaoflymphaticvasculaturehasbeenreported
[19, 20].
To study the relationship between lymphangiogenesis
mediated by VEGF-C and axillary lymph node metastasis,
two-mouse mammary carcinoma cell lines with diﬀerent
metastatic properties were used in this study. Both cell lines
were derived from the same BALB/c mouse, one of them, the
BJMC338 cell line, an adenocarcinoma cell line, has a low
metastaticpropensity,whereastheothercellline,BJMC3879,
hasa high metastatic propensity, particularlytolymph nodes
and lungs [21]. Each cell line was injected separately into
two groups of adult female BALB/c mice creating in vivo
mammary cancer models. In this inoculation study, we
found that increased expression of tumor-derived VEGF-C
correlates with LVD and axillary lymph node metastasis.International Journal of Breast Cancer 3
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Figure 2: Histopathology of the inoculated tumors at 10 weeks postinoculation. H&E staining (a and b) show viable region (white ∗)a n d
necrotic region (black ∗) in BJMC338 tumor (a) and BJMC3879 tumor (b). TEM micrographs (c and d) indicate tumor cells in the viable
region of BJMC338 tumor (c) and BJMC3879 tumor (d).
2.MaterialsandMethods
2.1. In Vitro Studies
2.1.1. Cell Culture and Cell Preparation. Two-mouse mam-
mary carcinoma cell lines were used in this study. The
BJMC338 mammary adenocarcinoma cell line used in this
studywasderivedfromafemaleBALB/c mouseinfectedwith
mouse mammary tumor virus (MMTV) into the inguinal
mammary glands and shows low metastatic property. The
BJMC3879 mammary adenocarcinoma cell line was derived
from foci within metastatic lymph node and lung of a female
BALB/c mouse that had been injected with BJMC338 cell
lineintotherightinguinalregion.TheBJMC3879mammary
cell line shows a high metastatic propensity, especially to
lymph nodes and lungs [22]. Both cell lines were maintained
in RPMI 1640 medium containing 10% fetal bovine serum
(FBS)withstreptomycin/penicillininanincubatorunder5%
CO2. The cells were immediately rinsed with 0.01M phos-
phatebuﬀeredsaline(PBS),ﬁxedwith2%paraformaldehyde
and2.5%glutaraldehydein0.1Mphosphatebuﬀer(PB)(pH
7.4) for 1h, for transmission electron microscopy (TEM).
Cells were subsequently postﬁxed in 1% OsO4 for 45min at
room temperature, dehydrated in a series of graded ethanol
concentrations,clearedinpropyleneoxide,andembeddedin
an epoxy resin mixture. For immunoﬂuorescent study, cells
were ﬁxed with 1% paraformaldehyde in PBS for 10min.
Table 1: Number of mice which have lung and axially lymphnode
metastases. Metastases were conﬁrmed by H&E staining.
Lung 4W 6W 8W 10W
BJMC338 0 0 0 0
BJMC3879 0 0 5 5
Axially lymph node 4W 6W 8W 10W
BJMC338 0 0 0 0
BJMC3879 0 5 5 5
2.1.2. TEM. After preparation, ultrathin sections were pre-
pared and stained with uranyl acetate and lead citrate. Sixty
nm sections were examined by TEM using H-7100 and H-
7650 (Hitachi, Tokyo, Japan).
2.1.3. Immunoﬂuorescent Study. Following ﬁxation, cells
were transferred to PBS for 15min, followed by exposure
to 1% Block Ace (Dainippon Sumitomo Pharma Co., Ltd.,
Tokyo,Japan)for20mintoblocknonspeciﬁcantibodybind-
ing. Cells were then incubated with a primary rabbit anti-
VEGF-C antibody (rabbit polyclonal; Santa Cruz Biotech-
nology, Santa Cruz, Calif, USA) for 1h at room temperature
(RT). After rinse in PBS for 15min, cells were incubated with
a secondary ﬂuorescein-isothiocyanate- (FITC-) conjugated
anti-rabbit antibody (Dako, Carpenteria, Calif, USA) for4 International Journal of Breast Cancer
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Figure 3: Histopathology by H&E staining of axially lymph nodes (a and b) and lungs (c and d) in mice at 10 weeks postinoculation. Axially
lymph node and lung in BJMC338 tumor (a and c) show normal appearance, whereas those of BJMC3879 tumor (b and d) demonstrate
metastatic foci.
30min at RT. Samples were counterstained with propidium
iodide (PI) for 15min and observed under a model Radiance
2000MP confocal scanning laser microscopy (Bio-Rad,
Hercules, Calif, USA).
2.1.4. Western Blot Analysis for VEGF-C Protein. Samples
containing 20μg of protein from cultured cells and tumors
were fractionated in 10% Tris-glycine gels under reduc-
ing conditions and transferred onto nitrocellulose mem-
brane. Anti-VEGF-C antibody (Santa Cruz Biotechnology)
was applied to membranes, incubated with appropriate
horseradish peroxidase-conjugated secondary antibody, and
visualized on X-ray ﬁlms using enhanced chemilumines-
cence (Perkin Elmer Life Science, Inc., Boston, Mass, USA).
2.1.5. RNA Preparation and Reverse Transcription-Polymerase
Chain Reaction (RT-PCR). Total RNA was isolated from
cultured BJMC338 and BJMC3879 cells using an RNeasy
Mini Kit (Qiagen, Hilden, Germany) and cDNA Synthesis
Kit (Roche Diagnostic Kit, Hilden, Germany) following the
manufacturer’sprotocol,withthetotalmRNAconcentration
adjusted to 5μg/μL in each sample. Primer sequences
for VEGF-C were 5 -CCTTCTTTAAACCTCCATGTGT-
3  and 5 -GCAAAACTGATTGTGACTGGT-3 ;f o rg l y c -
eraldehyde-3-phosphate dehydrogenase (GAPDH) used as
internal control 5 -TGCACGGGAAGCTCACTGG-3 ,5  -
TCCACCACCCTGTTGCTGTA-3  (Nihon Gene Research
Laboratories, Sendai, Japan). Products were ampliﬁed in a
GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, Calif, USA) with preincubation at 98◦Cf o r3 m i n
followed by 30 cycles of 94◦C for 30s, 58◦Cf o r3 0 s ,
and 72◦C for 60s. The ampliﬁcation was ﬁnished with a
single-3min incubation at 72◦C. The PCR products were
separated on 1.5% agarose gels, stained with 0.1mg/mL
ethidium bromide, visualized by UV transillumination, and
documented on black and white instant ﬁlms.
2.2. In Vivo Studies
2.2.1. Animals and Preparation of Tumors. A total of 40
female 6-week-old BALB/c mice (Japan SLC Inc., Hama-
matsu, Japan) were used in this study. All manipulations
of mice were performed in accordance with the procedures
outlined in the Guide for Care and Use of Laboratory
Animals in Osaka Medical College. Mice were divided into
two groups (20 mice each), and BJMC338 and BJMC3879
cells (5 × 106 cells/0.3mL in PBS) were inoculated subcu-
taneously into right inguinal region, respectively. Mice were
sacriﬁced at 4, 6, 8, 10 weeks after inoculation under ether
anesthesia.TumorsampleswerefrozenforWesternblotassay
and RT-PCR. Another one was ﬁxed for histopathology and
immunohistochemistry with 4 or 10% paraformaldehyde,
and for electron microscopy in a same ﬁxative as in vitro
study. Lungs and right axillary lymph nodes of mice wereInternational Journal of Breast Cancer 5
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Figure 4: Immunohistochemistry of LYVE-1 in BJMC338 tumors (a, c, e, and g) and BJMC3879 tumors (b, d, f, and h) at 4 weeks (a and
b), 6 weeks (c and d), 8 weeks (e and f), and 10 weeks postinoculation (g and h). Note the upregulation of LYVE-1 in BJMC3879 tumors.
removed and then ﬁxed as same as tumors. Samples ﬁxed
with paraformaldehyde were processed through to paraﬃn
embedding.
2.2.2. Histopathology and Immunohistochemistry. To exam-
ine histopathology and metastasis, tumors, lungs, and
light axillary lymph nodes were stained with Hematoxylin
and Eosin (H&E). Ultrastructural features of tumors were
checked under TEM. The avidin-biotin complex method
was used for immunohistochemistry. To visualize lymphatic
vessels, tumors were stained with primary antibodies to
the lymphatic-speciﬁc marker, lymphatic vessel endothelial6 International Journal of Breast Cancer
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Figure 5: Density of lymphatic vessels (LVD) in tumors. The LVD
inBJMC3879tumors(blackbars)isalwayssigniﬁcantlyhigherthan
that of BJMC338 tumors (white bars) (∗P<0.01, ∗∗P<0.001).
hyaluronan receptor-1 (LYVE-1) (rabbit polyclonal, Acris
Antibodies GmbH, Hiddenhausen, Germany). VEGF-C
(Santa Cruz) was labeled on tumor sections, and activated
macrophages were demonstrated by CD68 antibody (rat
anti-mouse CD68, AbD Serotec, Oxford, UK).
2.2.3. Lymphatic Vessel Density (LVD) and Counting of
Macrophage. The number of lymphatic vessels immunola-
beled with anti-LYVE-1 antibody in tumor sections at 4 to
10 weeks postinoculation as well as the number of CD68-
positive cells in tumor sections at 4 weeks postinoculation
werecountedunderlightmicroscopyathighermagniﬁcation
(×200).
2.2.4. Statistical Analysis. The above-mentioned data were
analyzed by Student’s t-test. P<0.05 was considered
statistically signiﬁcant.
3. Results
3.1. In Vitro Studies
3.1.1. Ultrastructure and Expression of VEGF-C. Ultrastruc-
tural diﬀerences between BJMC338 and BJMC3879 cells
were investigated using TEM. Both cell lines showed the
same morphology under TEM (Figures 1(a) and 1(b)).
They had prominent nucleoli and dispersed small condensed
chromatin in their nuclei. By immunoﬂuorescent study,
VEGF-C was barely expressed in BJMC338 cells, whereas
moderately expressed in BJMC3879 cells (Figures 1(c) and
1(d)). The levels of VEGF-C protein in the two cell lines
were determined by Western blot; the intensity of the bands
was measured and corrected against β-actin intensity. A
moderate increase in the VEGF-C protein level was detected
in BJMC3879 cells (Figure 1(e)). RT-PCR analysis showed
higher VEGF-C mRNA expression in BJMC3879 cells than
in BJMC338 cells (Figure 1(f)).
3.2. In Vivo Studies
3.2.1. Histopathology and Metastasis. Histopathologically,
the two types of inoculated mammary carcinoma (BJMC338
and BJMC3879 tumors) proved to be moderately diﬀerenti-
ated adenocarcinomas. Both tumors were accompanied by a
viable region, a central necrosis, and an inﬂammatory region
(Figures 2(a) and 2(b)). The morphology of the tumor cells
in the viable region was the same as that of the cultured
cell lines (Figures 2(c) and 2(d)). Metastasis to axillary
lymph nodes or lungs at 8 and 10 weeks postinoculation was
validatedbytheobservationofsectionsstainedwithH&E.At
8 and 10 weeks postinoculation, no metastasis was observed
in the lymph nodes and lungs of mice that were inoculated
with BJMC338 cells (Figures 3(a) and 3(c)). In contrast, all
the mice inoculated with BJMC3879 cells showed distant
metastasis to axillary lymph nodes and lungs at 8 and 10
weeks postinoculation (Table 1, Figures 3(b) and 3(d)).
3.2.2. Lymphangiogenesis in Tumor Mouse Models. The lym-
phatic vessels in the tumor were detected by immunohisto-
chemistry using the antibody speciﬁc to lymphatic vessels,
LYVE-1. At 4 weeks postinoculation, few lymphatic vessels
were found in BJMC338 tumors (Figure 4(a)). At 6 weeks
postinoculation, several lymphatic vessels were observed in
intratumoral connective tissues and/or surrounding connec-
tive tissues (Figures 4(c), 4(e),a n d4(g)). Conversely, large
numbers of dilated lymphatic vessels with or without tumor
cells were observed within and around BJMC3879 tumors at
4 to 10 weeks postinoculation (Figures 4(b), 4(d), 4(f),a n d
4(h)).
3.2.3. Lymphatic Vessel Density (LVD). The LVD of
BJMC3879 tumors was always signiﬁcantly higher than
that of BJMC338 tumors (Figure 5). In BJMC338 tumors,
the LVD at 6 weeks postinoculation was signiﬁcantly higher
than that at 4 weeks postinoculation (P< 0.01), after that,
no signiﬁcant diﬀerence in the LVD was observed (Figure 5).
However, in BJMC3879 tumors, the diﬀerence in the LVD
between 8 and 10 weeks postinoculation was not signiﬁcant;
a signiﬁcant diﬀerence was detected between 6 and 8 weeks
postinoculation (P<0.001), namely, the LVD markedly
increased at 8 weeks postinoculation (Figure 5).
3.2.4. TEM for Lymphatic Vessels. The status and ultrastruc-
tural features of lymphatic vessels in inoculated tumors
were examined under TEM. Lymphatic capillaries were
observed in the connective tissue surrounding and inside
the tumors. They were distinguished from blood capillaries.
The examination of lymphatic capillaries revealed that they
had thin endothelium, abluminal protrusion of endothe-
lial cells, no pericyte, no lamina densa, and overlapping
junctions (Figures 6(a)–6(d)). Intraluminal tumor cells
were observed in their lumen (Figure 6(a)). Interestingly,
a leukocyte was shown to go into and/or out from theInternational Journal of Breast Cancer 7
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Figure 6: TEM micrographs of lymphatic vessels in BJMC3879 tumors at 10 weeks postinoculation (a) and 4 weeks postinoculation (b).
The boxed areas in (b) are observed with high-power view (c and d). (a) A leukocyte (∗) is seen between endothelial cells (arrows), whereas
tumor cells (arrowheads) are observed in the lumen. (b) Lymphatic capillary (arrow) and blood capillaries (arrowheads) are detected in the
connective tissue surrounding tumors. Casein-like droplet (arrow) is located in the opening junction (c), and characteristic over-lapping
junction (arrow) is showed (d).
lymphatic lumen (Figure 6(a)). Furthermore, the absorption
of caseinlike droplets into the lymphatic lumen was observed
(Figure 6(c)).
3.2.5. VEGF-C Expression in the Tumors. VEGF-C-positive
cells were localized mainly in the peripheral viable regions
of tumors. Immunohistochemical studies and Western blot
analyses clearly demonstrated weak expression of VEGF-C
in BJMC338 tumors (Figures 7(a) and 7(c)), relative to the
strong expression in BJMC3879 tumors (Figures 7(b) and
7(c)).
3.2.6. Distribution of CD68-Positive Macrophages in the
Tumors. CD68-positive macrophages were found mainly
in the viable regions of both tumors (Figure 8). CD68-
positve macrophages containing vacuoles in their cytoplasm
aggregated in the tumors. The density of macrophages in
BJMC3879 tumors was signiﬁcantly higher than that in
BJMC338 tumors (P<0.001) (Figure 8).
4. Discussion
In this study, we found that mouse mammary tumor cells
(BJMC3879) that have high metastatic propensity expressed
a higher level of VEGF-C than the mouse mammary
tumor cells (BJMC338) with low metastatic propensity,
and the inoculated BJMC3879 tumors expressed VEGF-
C equivalently to tumor cell lines. In highly metastatic
mouse mammary tumors (BJMC3879), LVD and the VEGF-
C expression level were higher than those in the poorly
metastatic mouse mammarytumors(BJMC338). BJMC3879
tumor cell inoculation resulted in axillary lymph node
and lung metastases, whereas no metastasis occurred after
BJMC338 tumor cell inoculation.
Therearesomeclinicalsurveysofhumanbreastcancerto
proveacausalrelationshipbetweenLVDandmalignancy,the
VEGF-C expression, lymph node metastasis, and prognosis
[1, 4, 5]. Increased LVD in breast cancer was correlated
with lymph node metastasis and VEGF-C expression. It was
concluded that a high LVD may be a signiﬁcant unfavorable
prognostic factor for long-term survival of breast cancer
patient. Our results correlate with their reports. Contrary
to the clinical importance of these LVDs and on the basis
of clinicopathological studies including breast cancers, it
is the hypothesized that intratumoral lymphatics have no
function. None of the breast carcinoma was found to contain
Ki-67-positive dividing endothelial cells of lymph vessels
[23], and by experimental microlymphangiography assay, no8 International Journal of Breast Cancer
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Figure 7: Immunohistochemistry (a and b) and Western blot analysis (c) of VEGF-C in BJMC338 tumor (a and c) and BJMC3879 tumor
(b and c) at 8 weeks postinoculation.
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Figure 8: Immunohistochemistry of CD68 in BJMC338 tumor (a) and BJMC3879 tumor (b) at 4 weeks postinoculation. The density of
macrophages in BJMC3879 tumors was signiﬁcantly higher than that in BJMC338 tumors (∗P<0.001) (c).International Journal of Breast Cancer 9
functional draining intratumoural lymphatics were found
[24]. They also found that the functional lymphatics in the
tumor margin alone were suﬃcient for lymphatic metastasis
[24, 25]. It was reported that the degree of axillary lymph
node metastasis increased in parallel with increasing LVD,
patients with a high peritumoral LVD had only 58% 5-year
distant disease-free survival as compared with 74% among
those with a low peritumoral LVD. In addition, the presence
of intratumoral lymph vessels was associated with neither
axillary nodal status nor survival [24]. Moreover, not only
LVD but also the size of peritumoral lymph vessels may be
a signiﬁcant consideration of lymph node metastasis [7].
As the enlarged lymphatics may collect interstitial ﬂuid and
cancer cells oozing from the tumor surface, it was suggested
using mouse hybridoma cells and their syngenic mice that
both peritumoral and intratumoral lymph vessels may play a
crucial role in metastasis [26].
VEGF-C expression in breast cancer has been considered
as a clinicopathological prognostic factor [8, 27–29]. How-
ever, a univariate study by Bando et al. revealed that high
VEGF-C expression level was signiﬁcantly associated with
a favorable prognosis for disease-free survival and overall
survival (e.g., high VEGF-C levels were associated with low-
grade tumors and a smaller size). Furthermore, multivariate
analysis conﬁrmed the independent prognostic value of
VEGF-C [30]. Watanabe et al. compared the expressions
of CD44 variants and VEGF-C as associated factors with
long-term prognosis, they concluded that there was no
association between VEGF-C expression and clinicopatho-
logical prognostic factor [31]. A clinicopathological study
using RT-PCR indicated that VEGF-C and VEGF-D were
involved in lymphatic vessel invasion prior to lymph node
metastasis, and their expression level decreased after the
o c c u r r e n c eo fl y m p hn o d em e t a s t a s i s[ 32]. In a retrospective
study of 61 cases, it was reported that LVD may serve as a
predictor of lymph node metastasis and a prognostic factor,
whereas VEGF-C and VEGF-D may play important roles in
lymphangiogenesis, making the carcinoma more aggressive
and leading to a poor prognosis in breast cancer [8].
Because of controversial results showing that high VEGF-C
levels are associated with low-grade tumors and a smaller
size, Bando et al. suggested that the mechanism of VEGF-
C protein processing in human cancer requires further
study [30]. Because intratumoral VEGF-C protein level
changes in response to intratumoral microenvironments, the
expressions of VEGF-C and VEGF-D may be inadequate as
clinicopathological prognostic factors by themselves.
To evaluate the eﬀect of VEGF-C on lymphangiogenesis
and lymph node metastasis, some human breast cancer cell
lines were used in vivo and xenotransplanted to immunode-
ﬁcientmice,SCIDmice,ornudemice[11,12].Usinghuman
MCF-7 breast cancer cells, which are poorly invasive and
estrogen dependent, Mattila et al. showed that tumor growth
was stimulated in vivo in VEGF-C overexpressing MCF-
7 cells xenotransplanted to nude mice. Furthermore, LVD
in intra- and peritumoral lymphatic vessels was increased
in tumors promoted by VEGF-C derived from xenotrans-
planted MCF-7 cells. While these reports, even though in
xenotransplanted mice, support our results that tumoral
VEGF-C expression plays an important role in lymphan-
giogenesis and lymph node metastasis of mouse mammary
carcinoma, the role of immune cells including macrophages
must be considered in tumor metastasis. Recent studies
showed that VEGF-C is secreted by TAMs [13–15]. Our
immunocompetent mouse models clearly showed the pres-
ence of CD68-positive TAMs in the inoculated tumors, and
thedensityofTAMsinthehigh-metastaticmousemodelwas
higher than that in the low-metastatic mouse model.
5. Conclusion
TheLVDinmammarycarcinomastronglyexpressingVEGF-
C was higher than that in carcinoma expressing a low
VEGF-C level with the former showing axillary lymph node
metastasis. Our inoculated mouse mammary carcinoma
models in this study are allotransplanted and immunocom-
petent tumors which show the same lymph node metastatic
spectrumashumanbreastcancers.Consequently,ourmouse
models are the most ideal for the study of lymph node
metastasis.
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